{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:35:03Z","timestamp":1785429303292,"version":"3.56.0"},"reference-count":22,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Roche"},{"id":[{"id":"https:\/\/ror.org\/006hrz834","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Objectives: To evaluate the association between European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) scores and treatment recommendations from European Society for Medical Oncology, National Comprehensive Cancer Network (NCCN), and American Society of Clinical Oncology (ASCO) in curative and metastatic breast cancer (BC), and to assess inter-guideline concordance. Methods: We conducted a comparative review of 47 systemic BC therapies with published ESMO-MCBS scores (accessed 30 June 2025). Guideline recommendations from ESMO, NCCN, and ASCO were extracted from the most recent versions and harmonized into ordinal tiers. Associations between MCBS scores and recommendation categories were evaluated using Fisher\u2019s exact test and Spearman\u2019s rank correlation in the palliative setting. Curative therapies were analyzed descriptively due to limited variability. Results: Among 38 palliative therapies, 40% achieved high clinical benefit (MCBS 4\u20135). A significant association was observed between MCBS scores and NCCN recommendations (p = 0.003; \u03c1 = 0.48), with 62% of NCCN Category 1 therapies demonstrating high benefit versus 13% in other categories. No significant associations were observed with ASCO (p = 0.101; \u03c1 = 0.18) or ESMO guideline recommendations (p = 0.073; \u03c1 = 0.19). Inter-guideline concordance was strongest between ASCO and ESMO (p = 0.033; \u03c1 = 0.48). In the curative setting (n = 9), most therapies received an MCBS grade A and top-tier guideline endorsement. Conclusions: Alignment between ESMO-MCBS and guideline recommendations is moderate and framework-dependent, strongest with NCCN in metastatic BC. Discordance primarily reflects differences between magnitude-of-benefit thresholds and evidence-certainty frameworks. ESMO-MCBS may serve as a complementary tool to enhance value-based clinical and policy decision-making.<\/jats:p>","DOI":"10.3390\/curroncol33040227","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:53:46Z","timestamp":1776426826000},"page":"227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Scores with Guideline Recommendations in Breast Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Bushra","family":"Salman","sequence":"first","affiliation":[{"name":"Pharmacy Department, National Hematology and Bone Marrow Transplant Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intissar","family":"Yehia","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadil","family":"Al Sharqi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roula","family":"Al Shidi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaad A.","family":"Al Dhahri","sequence":"additional","affiliation":[{"name":"Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Al Ghefeili","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Makhloufi","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Al Ajmi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5705-7307","authenticated-orcid":false,"given":"Suhaila","family":"Al Farsi","sequence":"additional","affiliation":[{"name":"Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayana","family":"Al Kiyumi","sequence":"additional","affiliation":[{"name":"Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-5675","authenticated-orcid":false,"given":"Zaid Riyadh Raouf","family":"Al Ishaq","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Abdelhakim","family":"Ayaad","sequence":"additional","affiliation":[{"name":"Department of Quality and Accreditation, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2116-4536","authenticated-orcid":false,"given":"Khalid","family":"Al Baimani","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/annonc\/mdw538","article-title":"Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?","volume":"28","author":"Azariah","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_6","first-page":"e2300285","article-title":"Systemic Treatment of Patients with Metastatic Breast Cancer: ASCO Resource-Stratified Guideline","volume":"10","author":"Temin","year":"2024","journal-title":"JCO Glob. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: A cost-benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S1470-2045(24)00505-9","article-title":"Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: A retrospective analysis","volume":"25","author":"Kanavos","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_11","unstructured":"ESMO (2026, January 20). ESMO-MCBS Scorecards. Available online: https:\/\/www.esmo.org\/frameworks-and-tools\/esmo-mcbs\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.32604\/or.2024.048948","article-title":"Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelines","volume":"32","author":"Skelin","year":"2024","journal-title":"Oncol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.athoracsur.2020.03.022","article-title":"National Comprehensive Cancer Network Guidelines: Who Makes Them? What Are They? Why Are They Important?","volume":"110","author":"Pluchino","year":"2020","journal-title":"Ann. Thorac. Surg."},{"key":"ref_14","unstructured":"ASCO (2026, January 20). Guideline Methodology. Available online: https:\/\/www.asco.org\/practice-patients\/guidelines\/guideline-methodology#."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e066045","DOI":"10.1136\/bmj-2021-066045","article-title":"Discordant and inappropriate discordant recommendations in consensus and evidence based guidelines: Empirical analysis","volume":"375","author":"Yao","year":"2021","journal-title":"BMJ"},{"key":"ref_22","first-page":"253","article-title":"Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry","volume":"10","author":"Slomiany","year":"2017","journal-title":"Am. Health Drug Benefits"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T04:17:17Z","timestamp":1776572237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040227"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040227","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}